Genetic therapy for the nervous system

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Bowers, William J ^a   Breakefield, Xandra O ^b   Sena Esteves, Miguel ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; RNA; VIRUS VECTOR;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN TUMOR; CLINICAL TRIAL; GENE MUTATION; GENE THERAPY; HUMAN; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; STEM CELL;

ALZHEIMER DISEASE; GENE THERAPY; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LYSOSOMAL STORAGE DISEASES; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RNA SPLICING;

EID: 79956056971     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr110     Document Type: Article

References (188)

1. Abbott, N.J., Ronnback, L. and Hansson, E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 7, 41-53.
2. Armulik, A., Genové, G., Mäe, M., Nisancioglu, M.H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K. et al. (2010) Pericytes regulate the blood-brain barrier. Nature, 468, 557-561.
3. Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L. and Oldfield, E.H. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA, 91, 2076-2080.
4. Salegio, E.A., Kells, A.P., Richardson, R.M., Hadaczek, P., Forsayeth, J., Bringas, J., Sardi, S.P., Passini, M.A., Shihabuddin, L.S., Cheng, S.H. et al. (2010) Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum. Gene Ther., 21, 1093-1103.
5. Passini, M.A., Watson, D.J., Vite, C.H., Landsburg, D.J., Peigenbaum, A.L. and Wolfe, J.H. (2003) Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol., 77, 7034-7040.
6. Watson, G., Bastacky, J., Belichenko, P., Buddhikot, M., Jungles S., Vellard, M., Mobley, W.C. and Kakkis, E. (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther., 13, 917-925.
7. Cearley, C.N., Vandenberghe, L.H., Parente, M.K., Carnish, E.R., Wilson, J.M. and Wolfe, J.H. (2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther., 16, 1710-1718.
8. Liu, G., Martins, I.H., Chiorini, J.A. and Davidson, B.L. (2005) Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther., 12, 1503-1508.
9. Meijer, D.H., Maguire, C.A., LeRoy, S.G. and Sena-Esteves, M. (2009) Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther., 16, 664-671.
10. Dickson, P., McEntee, M., Vogler, C., Le, S., Levy, B., Peinovich, M., Hanson, S., Passage, M. and Kakkis, E. (2007) Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab., 91, 61-68.
11. Chang, M., Cooper, J.D., Sleat, D.E., Cheng, S.H., Dodge, J.C., Passini, M.A., Lobel, P. and Davidson, B.L. (2008) Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther., 16, 649-656.
12. Pardridge, W.M. (2010) Biopharmaceutical drug targeting to the brain. J. Drug Target, 18, 157-167.
13. Osborn, M.J., McElmurry, R.T., Peacock, B., Tolar, J. and Blazar B.R. (2008) Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol. Ther., 16, 1459-1466.
14. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M. and Kaspar, B.K. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol., 27, 59-65.
15. Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.M., Fyfe, J., Moullier, P., Colle, M.A. and Barkats, M. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther., 17, 1187-1196.
16. Louboutin, J.P., Chekmasova, A.A., Marusich, E., Chowdhury, J.R. and Strayer, D.S. (2010) Efficient CNS gene delivery by intravenous injection. Nat. Methods, 7, 905-907.
17. Chen, Y.H., Chang, M. and Davidson, B.L. (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med., 15, 1215-1218.
18. Biffi, A., De Palma, M., Quattrini, A., Del Carro, U., Amadio, S., Visigalli, I., Sessa, M., Fasano, S., Brambilla, R., Marchesini, S. et al. (2004) Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest., 113, 1118-1129.
19. De Palma, M., Mazzieri, R., Politi, L.S., Pucci, F., Zonari, E., Sitia, G., Mazzoleni, S., Moi, D., Venneri, M.A., Indraccolo, S. et al. (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell, 14, 299-311.
20. Aboody, K.S., Brown, A., Rainov, N., Bower, K., Liu, S., Yang, W., Small, J., Herrlinger, U., Ourednik, V., Black, P. et al. (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA, 97, 12846-12851.
21. Stitelman, D.H., Endo, M., Bora, A., Muvarak, N., Zoltick, P.W., Flake, A.W. and Brazelton, T.R. (2010) Robust in vivo transduction of nervous system and neural stem cells by early gestational intra amniotic gene transfer using lentiviral vector. Mol. Ther., 18, 1615-1623.
22. Zhang, Y., Calon, F., Zhu, C., Boado, R.J. and Pardridge, W.M. (2003b) Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther., 14, 1-12.
23. Stachowiak, E.K., Roy, I., Lee, Y.W., Capacchietti, M., Aletta, J.M., Prasad, P.N. and Stachowiak, M.K. (2009) Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain. Integr. Biol. (Camb.), 1, 394-403.
24. De Vry, J., Martinez-Martinez, P., Losen, M., Temel, Y., Steckler, T., Steinbusch, H.W., De Baets, M.H. and Prickaerts, J. (2010) In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog. Neurobiol., 92, 227-244.
25. Nagayama, S., Zeng, S., Xiong, W., Fletcher, M.L., Masurkar, A.V., Davis, D.J., Pieribone, V.A. and Chen, W.R. (2007) In vivo simultaneous tracing and Ca(2+) imaging of local neuronal circuits. Neuron, 53, 789-803.
26. Nevian, T. and Helmchen, F. (2007) Calcium indicator loading of neurons using single-cell electroporation. Pflugers Arch., 454, 675-688.
27. Chesler, A.T., Le Pichon, C.E., Brann, J.H., Araneda, R.C., Zou, D.J. and Firestein, S. (2008) Selective gene expression by postnatal electroporation during olfactory interneuron neurogenesis. PLoS ONE, 3, e1517.
28. Hadaczek, P., Eberling, J.L., Pivirotto, P., Bringas, J., Forsayeth, J. and Bankiewicz, K.S. (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther., 18, 1458-1461.
29. Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D. et al. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 369, 2097-2105.
30. Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., Ballon, D., Heier, L., Greenwald, B.M. et al. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19, 463-474.
31. Eberling, J.L., Jagust, W.J., Christine, C.W., Starr, P., Larson, P., Bankiewicz, K.S. and Aminoff, M.J. (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 70, 1980-1983.
32. Christine, C.W., Starr, P.A., Larson, P.S., Eberling, J.L., Jagust, W.J., Hawkins, R.A., VanBrocklin, H.F., Wright, J.F., Bankiewicz, K.S. and Aminoff, M.J. (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73, 1662-1669.
33. McPhee, S.W., Janson, C.G., Li, C., Samulski, R.J., Camp, A.S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A. et al. (2006) Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med., 8, 577-588.
34. Barcia, C., Jimenez-Dalmaroni, M., Kroeger, K.M., Puntel, M., Rapaport, A.J., Larocque, D., King, G.D., Johnson, S.A., Liu, C., Xiong, W. et al. (2007) One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol. Ther., 15, 2154-2163.
35. Oehmig, A., Fraefel, C. and Breakefield, X.O. (2004) Update of herpesvirus amplicon vectors. Mol. Ther., 10, 630-643.
36. Peruzzi, P.P., Lawler, S.E., Senior, S.L., Dmitrieva, N., Edser, P.A., Gianni, D., Chiocca, E.A. and Wade-Martins, R. (2009) Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. Mol. Ther., 17, 1517-1526.
37. Lufino, M.M., Edser, P.A. and Wade-Martins, R. (2008) Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol. Ther., 16, 1525-1538.
38. Hickman, S., Shapiro, L.J. and Neufeld, E.F. (1974) A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. Biochem. Biophys. Res. Commun., 57, 55-61.
39. Skorupa, A.F., Fisher, K.J., Wilson, J.M., Parente, M.K. and Wolfe, J.H. (1999) Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol., 160, 17-27.
40. Bosch, A., Perret, E., Desmaris, N. and Heard, J.M. (2000) Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther., 1, 63-70.
41. Bosch, A., Perret, E., Desmaris, N., Trono, D. and Heard, J.M. (2000) Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther., 11, 1139-1150.
42. Consiglio, A., Quattrini, A., Martino, S., Bensadoun, J.C., Dolcetta, D., Trojani, A., Benaglia, G., Marchesini, S., Cestari, V., Oliverio, A. et al. (2001) In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med., 7, 310-316.
43. Passini, M.A., Macauley, S.L., Huff, M.R., Taksir, T.V., Bu, J., Wu, I.H., Piepenhagen, P.A., Dodge, J.C., Shihabuddin, L.S., O'Riordan, C.R. et al. (2005) AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther., 11, 754-762.
44. Passini, M.A., Bu, J., Fidler, J.A., Ziegler, R.J., Foley, J.W., Dodge, J.C., Yang, W.W., Clarke, J., Taksir, T.V., Griffiths, D.A. et al. (2007) Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl Acad. Sci. USA, 104, 9505-9510.
45. Passini, M.A., Dodge, J.C., Bu, J., Yang, W., Zhao, Q., Sondhi, D., Hackett, N.R., Kaminsky, S.M., Mao, Q., Shihabuddin, L.S. et al. (2006) Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci., 26, 1334-1342.
46. Davidson, B.L., Stein, C.S., Heth, J.A., Martins, I., Kotin, R.M., Derksen, T.A., Zabner, J., Ghodsi, A. and Chiorini, J.A. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl Acad. Sci. USA, 97, 3428-3432.
47. Taylor, R.M. and Wolfe, J.H. (1997) Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med., 3, 771-774.
48. Passini, M.A., Lee, E.B., Heuer, G.G. and Wolfe, J.H. (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci., 22, 6437-6446.
49. Hennig, A.K., Levy, B., Ogilvie, J.M., Vogler, C.A., Galvin, N., Bassnett, S. and Sands, M.S. (2003) Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci., 23, 3302-3307.
50. Dodge, J.C., Clarke, J., Song, A., Bu, J., Yang, W., Taksir, T.V., Griffiths, D., Zhao, M.A., Schuchman, E.H., Cheng, S.H. et al. (2005) Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc. Natl Acad. Sci. USA, 102, 17822-17827.
51. Cearley, C.N. and Wolfe, J.H. (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci., 27, 9928-9940.
52. Baek, R.C., Broekman, M.L., Leroy, S.G., Tierney, L.A., Sandberg, M.A., d'Azzo, A., Seyfried, T.N. and Sena-Esteves, M. (2010) AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS ONE, 5, e13468.
53. Lattanzi, A., Neri, M., Maderna, C., di Girolamo, I., Martino, S., Orlacchio, A., Amendola, M., Naldini, L. and Gritti, A. (2010) Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Hum. Mol. Genet., 19, 2208-2227.
54. Vite, C.H., McGowan, J.C., Niogi, S.N., Passini, M.A., Drobatz, K.J., Haskins, M.E. and Wolfe, J.H. (2005) Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol., 57, 355-364.
55. Ciron, C., Desmaris, N., Colle, M.A., Raoul, S., Joussemet, B., Verot, L., Ausseil, J., Froissart, R., Roux, F., Cherel, Y. et al. (2006) Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol., 60, 204-213.
56. Biffi, A., Capotondo, A., Fasano, S., del Carro, U., Marchesini, S., Azuma, H., Malaguti, M.C., Amadio, S., Brambilla, R., Grompe, M. et al. (2006) Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest., 116, 3070-3082.
57. Gentner, B., Visigalli, I., Hiramatsu, H., Lechman, E., Ungari, S., Giustacchini, A., Schira, G., Amendola, M., Quattrini, A., Martino, S. et al. (2010) Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med., 2, 58-84.
58. Visigalli, I., Delai, S., Politi, L.S., Di Domenico, C., Cerri, F., Mrak, E., D'Isa, R., Ungaro, D., Stok, M., Sanvito, F. et al. (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood, 116, 5130-5139.
59. Bartus, R.T., Dean, R.L., Beer, B. 3rd and Lippa, A.S. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408-414.
60. Coyle, J.T., Price, D.L. and DeLong, M.R. (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219, 1184-1190.
61. Masliah, E., Terry, R.D., Alford, M., DeTeresa, R. and Hansen, L.A. (1991) Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol., 138, 235-246.
62. Perry, E.K., Perry, R.H., Blessed, G. and Tomlinson, B.E. (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol., 4, 273-277.
63. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. and Perry, R.H. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J., 2, 1457-1459.
64. Blesch, A. and Tuszynski, M. (1995) Ex vivo gene therapy for Alzheimer's disease and spinal cord injury. Clin. Neurosci., 3, 268-274.
65. Tuszynski, M.H. and Gage, F.H. (1995) Bridging grafts and transient nerve growth factor infusions promote long-term central nervous system neuronal rescue and partial functional recovery. Proc. Natl Acad. Sci. USA, 92, 4621-4625.
66. Tuszynski, M.H. and Gage, F.H. (1990) Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. Acta Neurobiol. Exp. (Warsz.), 50, 311-322.
67. Tuszynski, M.H., Senut, M.C., Ray, J. and Roberts, J. (1994) Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secrete nerve growth factor. Neurobiol. Dis., 1, 67-78.
68. Rosenberg, M.B., Friedmann, T., Robertson, R.C., Tuszynski, M., Wolff, J.A., Breakefield, X.O. and Gage, F.H. (1988) Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science, 242, 1575-1578.
69. Tuszynski, M.H., Thal, L., Pay, M., Salmon, D.P., U, H.S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G. et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 11, 551-555.
70. Zhang, J., Wu, X., Qin, C., Qi, J., Ma, S., Zhang, H., Kong, Q., Chen, D., Ba, S. and He, W. (2003a) A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis., 14, 365-379.
71. Bowers, W.J., Mastrangelo, M.A., Stanley, H.A., Casey, A.E., Milo, L.J.J. and Federoff, H.J. (2005) HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging, 26, 393-407.
72. Kim, H.D., Maxwell, J.A., Kong, F.K., Tang, D.C. and Fukuchi, K. (2005) Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem. Biophys. Res. Commun., 336, 84-92.
73. Fukuchi, K., Tahara, K., Kim, H.D., Maxwell, J.A., Lewis, T.L., Accavitti-Loper, M.A., Kim, H., Ponnazhagan, S. and Lalonde, R. (2006) Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis., 23, 502-511.
74. Levites, Y., Jansen, K., Smithson, L.A., Dakin, R., Holloway, V.M., Das, P. and Golde, T.E. (2006) Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci., 26, 11923-11928.
75. Ryan, D.A., Mastrangelo, M.A., Narrow, W.C., Sullivan, M.A., Federoff, H.J. and Bowers, W.J. (2010) Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol. Ther., 18, 1471-1481.
76. Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., Verma, I.M. and Masliah, E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci., 23, 1992-1996.
77. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J. and Saido, T.C. (2001) Metabolic regulation of brain Abeta by neprilysin. Science, 292, 1550-1552.
78. Lebson, L., Nash, K., Kamath, S., Herber, D., Carty, N., Lee, D.C., Li, Q., Szekeres, K., Jinwal, U., Koren, J. et al. (2010) Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J. Neurosci., 30, 9651-9658.
79. Thinakaran, G. (1999) The role of presenilins in Alzheimer's disease. J. Clin. Invest., 104, 1321-1327.
80. Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T. and Selkoe, D.J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 398, 513-517.
81. Singer, O., Marr, R.A., Rockenstein, E., Crews, L., Coufal, N.G., Gage, F.H., Verma, I.M. and Masliah, E. (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci., 8, 1343-1349.
82. Hong, C.S., Goins, W.F., Goss, J.R., Burton, E.A. and Glorioso, J.C. (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther., 13, 1068-1079.
83. Hudry, E., Van Dam, D., Kulik, W., De Deyn, P.P., Stet, F.S., Ahouansou, O., Benraiss, A., Delacourte, A., Bougne'res, P., Aubourg, P. et al. (2010) Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther., 18, 44-53.
84. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P. et al. (2010) In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther., 18, 1450-1457.
85. Shulman, J.M., De Jager, P.L. and Feany, M.B. (2011) Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol., 6, 193-222.
86. Klein, C. and Schlossmacher, M.G. (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology, 69, 2093-2104.
87. Kells, A.P., Eberling, J., Su, X., Pivirotto, P., Bringas, J., Hadaczek, P., Narrow, W.C., Bowers, W.J., Federoff, H.J., Forsayeth, J. et al. (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J. Neurosci., 30, 9567-9577.
88. Marks, W.J.J., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L. et al. (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 9, 1164-1172
89. Manfredsson, F.P., Burger, C., Rising, A.C., Zuobi-Hasona, K., Sullivan, L.F., Lewin, A.S., Huang, J., Piercefield, E., Muzyczka, N. and Mandel, R.J. (2009) Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther., 17, 1857-1867.
90. Laganiere, J., Kells, A.P., Lai, J.T., Guschin, D., Paschon, D.E., Meng, X., Fong, L.K., Yu, Q., Rebar, E.J., Gregory, P.D. et al. (2010) An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J. Neurosci., 30, 16469-16474.
91. Azzouz, M., Martin-Rendon, E., Barber, R.D., Mitrophanous, K.A., Carter, E.E., Rohll, J.B., Kingsman, S.M., Kingsman, A.J. and Mazarakis, N.D. (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci., 22, 10302-10312.
92. Muñoz, A., Carlsson, T., Tronci, E., Kirik, D., Björklund, A. and Carta, M. (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol., 219, 298-307.
93. Muramatsu, S., Fujimoto, K., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T. et al. (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther., 18, 1731-1735.
94. Feigin, A., Kaplitt, M.G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M.J. and Eidelberg, D. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc. Natl Acad. Sci. USA, 104, 19559-19564.
95. Lindvall, O. and Kokaia, Z. (2009) Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci., 30, 260-267.
96. Dawson, T.M., Ko, H.S. and Dawson, V.L. (2010) Genetic animal models of Parkinson's disease. Neuron, 66, 646-661.
97. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
98. Nemani, V.M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M.K., Chaudhry, F.A., Nicoll, R.A. and Edwards, R.H. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
99. Yamada, M., Mizuno, Y. and Mochizuki, H. (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum. Gene Ther., 16, 262-270.
100. Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., de Moura, A.P., Voit, T. et al. (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet., 20, 681-693.
101. Foust, K.D., Wang, X., McGovern, V.L., Braun, L., Bevan, A.K., Haidet, A.M., Le, T.T., Morales, P.R., Rich, M.M., Burghes, A.H. et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol., 28, 271-274.
102. Lorson, C.L., Rindt, H. and Shababi, M. (2010) Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum. Mol. Genet., 19, R111-R118.
103. Cartegni, L. and Krainer, A.R. (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol., 10, 120-125.
104. Williams, J.H., Schray, R.C., Patterson, C.A., Ayitey, S.O., Tallent, M.K. and Lutz, G.J. (2009) Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci., 29, 7633-7638.
105. Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M.A., Bennett, C.F. and Krainer, A.R. (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev., 24, 1634-1644.
106. Coady, T.H. and Lorson, C.L. (2010) Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J. Neurosci., 30, 126-130.
107. Greenway, M.J., Andersen, P.M., Russ, C., Ennis, S., Cashman, S., Donaghy, C., Patterson, V., Swingler, R., Kieran, D., Prehn, J. et al. (2006) ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet., 38, 411-413.
108. Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J.C., Williams, K.L., Buratti, E. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319, 1668-1672.
109. Kwiatkowski, T.J., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T. et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205-1208.
110. Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P. et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323, 1208-1211.
111. Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y., Kinoshita, Y., Kamada, M., Nodera, H., Suzuki, H. et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 465, 223-226.
112. Dion, P.A., Daoud, H. and Rouleau, G.A. (2009) Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat. Rev. Genet., 10, 769-782.
113. Ezzi, S.A., Urushitani, M. and Julien, J.P. (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem., 102, 170-178.
114. Bosco, D.A., Morfini, G., Karabacak, N.M., Song, Y., Gros-Louis, F., Pasinelli, P., Goolsby, H., Fontaine, B.A., Lemay, N., McKenna-Yasek, D. et al. (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci., 13, 1369-1403.
115. Israelson, A., Arbel, N., Da Cruz, S., Ilieva, H., Yamanaka, K., Shoshan-Barmatz, V. and Cleveland, D.W. (2010) Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron, 67, 575-587.
116. Dodge, J.C., Treleaven, C.M., Fidler, J.A., Hester, M., Haidet, A., Handy, C., Rao, M., Eagle, A., Matthews, J.C., Taksir, T.V. et al. (2010) AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol. Ther., 18, 2075-2084.
117. Dodge, J.C., Haidet, A.M., Yang, W., Passini, M.A., Hester, M., Clarke, J., Roskelley, E.M., Treleaven, C.M., Rizo, L., Martin, H. et al. (2008) Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther., 16, 1056-1064.
118. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D. and Gage, F.H. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 301, 839-842.
119. Azzouz, M., Ralph, G.S., Storkebaum, E., Walmsley, L.E., Mitrophanous, K.A., Kingsman, S.M., Carmeliet, P. and Mazarakis, N.D. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature, 429, 413-417.
120. Ding, H., Schwarz, D.S., Keene, A., Affarel, B., Fenton, L., Xia, X., Shi, Y., Zamore, P.D. and Xu, Z. (2003) Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell, 2, 209-217.
121. Ralph, G.S., Radcliffe, P.A., Day, D.M., Carthy, J.M., Leroux, M.A., Lee, D.C., Wong, L.F., Bilsland, L.G., Greensmith, L., Kingsman, S.M. et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med., 11, 429-433.
122. Raoul, C., Abbas-Terki, T., Bensadoun, J.C., Guillot, S., Haase, G., Szulc, J., Henderson, C.E. and Aebischer, P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med., 11, 423-428.
123. Xia, X., Zhou, H., Huang, Y. and Xu, Z. (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis., 23, 578-586.
124. Boillée, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A., Kassiotis, G., Kollias, G. and Cleveland, D.W. (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science, 312, 1389-1392.
125. Urushitani, M., Ezzi, S.A. and Julien, J.P. (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA, 104, 2495-2500.
126. Gros-Louis, F., Soucy, G., Lariviere, R. and Julien, J.P. (2010) Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem., 113, 1188-1199.
127. Bleau, A.M., Huse, J.T. and Holland, E.C. (2009) The ABCG2 resistance network of glioblastoma. Cell Cycle, 8, 2936-2944.
128. Plotkin, S.R., Stemmer-Rachamimov, A.O., Barker, F.G. 2nd, Halpin, C., Padera, T.P., Tyrrell, A., Sorensen, A.G., Jain, R.K. and di Tomaso, E. (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med., 361, 358-367.
129. Lucio-Eterovic, A.K., Piao, Y. and de Groot, J.F. (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res., 15, 4589-4599.
130. Määttä, A.M., Samaranayake, H., Pikkarainen, J., Wirth, T. and Ylä-Herttuala, S. (2009) Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr. Gene Ther., 9, 356-367.
131. Bourbeau, D., Lavoie, G., Nalbantoglu, J. and Massie, B. (2004) Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. J. Gene Med., 6, 1320-1332.
132. Tyminski, E., Leroy, S., Terada, K., Finkelstein, D.M., Hyatt, J.L., Danks, M.K., Potter, P.M., Saeki, Y. and Chiocca, E.A. (2005) Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res., 65, 6850-6857.
133. Fulci, G. and Chiocca, E.A. (2007) Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. Expert Opin. Biol. Ther., 7, 197-208.
134. Zemp, F.J., Corredor, J.C., Lun, X., Muruve, D.A. and Forsyth, P.A. (2010) Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev., 21, 103-117.
135. Goetz, C. and Gromeier, M. (2010) Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev., 21, 197-203.
136. Lun, X., Chan, J., Zhou, H., Sun, B., Kelly, J.J., Stechishin, O.O., Bell, J.C., Parato, K., Hu, K., Vaillant, D. et al. (2010) Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol. Ther., 18, 1927-1936.
137. Aboody, K.S., Najbauer, J. and Danks, M.K. (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther., 15, 739-752.
138. Bexell, D., Scheding, S. and Bengzon, J. (2010) Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol. Ther., 18, 1067-1075.
139. Frank, R.T., Najbauer, J. and Aboody, K.S. (2010) Concise review: stem cells as an emerging platform for antibody therapy of cancer. Stem Cells, 28, 2084-2087.
140. Balyasnikova, I.V., Ferguson, S.D., Sengupta, S., Han, Y. and Lesniak, M.S. (2010) Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE, 5, e9750.
141. Yong, R.L., Shinojima, N., Fueyo, J., Gumin, J., Vecil, G.G., Marini, F.C., Bogler, O., Andreeff, M. and Lang, F.F. (2009) Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res., 69, 8932-8940.
142. Herrlinger, U., Woiciechowski, C., Sena-Esteves, M., Aboody, K.S., Jacobs, A.H., Rainov, N.G., Snyder, E.Y. and Breakefield, X.O. (2000) Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol. Ther., 1, 347-357.
143. Shah, K., Bureau, E., Kim, D.E., Yang, K., Tang, Y., Weissleder, R. and Breakefield, X.O. (2005) Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol., 57, 34-41.
144. Lorico, A., Mercapide, J., Solodushko, V., Alexeyev, M., Fodstad, O. and Rappa, G. (2008) Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther., 15, 605-615.
145. Sampson, J.H., Archer, G.E., Mitchell, D.A., Heimberger, A.B., Herndon, J.E. 2nd, Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D.A., Friedman, A.H. et al. (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther., 8, 2773-2779.
146. Krisky, D.M., Marconi, P.C., Oligino, T.J., Rouse, R.J., Fink, D.J., Cohen, J.B., Watkins, S.C. and Glorioso, J.C. (1998) Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther., 5, 1517-1530.
147. Kahlon, K.S., Brown, C., Cooper, L.J., Raubitschek, A., Forman, S.J. and Jensen, M.C. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res., 64, 9160-9166.
148. Maguire, C.A., Meijer, D.H., LeRoy, S.G., Tierney, L.A., Broekman, M., Costa, F., Breakefield, X.O., Stemmer-Rachamimov, A. and Sena-Esteves, M. (2008) Preventing growth of brain tumors by creating a zone of resistance. Mol. Ther., 16, 1695-1702.
149. Jamieson, A.C., Miller, J.C. and Pabo, C.O. (2003) Drug discovery with engineered zinc-finger proteins. Nat. Rev. Drug Discov., 2, 361-368.
150. Pâques, F. and Duchateau, P. (2007) Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr. Gene Ther., 7, 49-66.
151. Simon, P., Cannata, F., Concordet, J.P. and Giovannangeli, C. (2008) Targeting DNA with triplex-forming oligonucleotides to modify gene sequence. Biochimie, 90, 1109-1116.
152. McLachlan, J., Fernandez, S., Helleday, T. and Bryant, H.E. (2009) Specific targeted gene repair using single-stranded DNA oligonucleotides at an endogenous locus in mammalian cells uses homologous recombination. DNA Repair (Amst.), 8, 1424-1433.
153. Kazuki, Y., Hoshiya, H., Takiguchi, M., Abe, S., Iida, Y., Osaki, M., Katoh, M., Hiratsuka, M., Shirayoshi, Y., Hiramatsu, K. et al. (2010) Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther., [Epub ahead of print, 18 November].
154. Moralli, D., Simpson, K.M., Wade-Martins, R. and Monaco, Z.L. (2006) A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors. EMBO Rep., 7, 911-918.
155. Bader, A.G., Brown, D. and Winkler, M. (2010) The promise of microRNA replacement therapy. Cancer Res., 70, 7027-7030.
156. Quinti, L., Chopra, V., Rotili, D., Valente, S., Amore, A., Franci, G., Meade, S., Valenza, M., Altucci, L., Maxwell, M.M. et al. (2010) Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr., 2, RRN1172.
157. Xie, J., Xie, Q., Zhang, H., Ameres, S.L., Hung, J.H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S. et al. (2011) MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther., 19, 526-535.
158. Brown, B.D., Venneri, M.A., Zingale, A., Sergi Sergi, L. and Naldini, L. (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med., 12, 585-591.
159. Brown, B.D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C. and Naldini, L. (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol., 25, 1457-1467.
160. Mazarakis, N.D., Azzouz, M., Rohll, J.B., Ellard, F.M., Wilkes, F.J., Olsen, A.L., Carter, E.E., Barber, R.D., Baban, D.F., Kingsman, S.M. et al. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet., 10, 2109-2121.
161. Rahim, A.A., Wong, A.M., Howe, S.J., Buckley, S.M., Acosta-Saltos, A.D., Elston, K.E., Ward, N.J., Philpott, N.J., Cooper, J.D., Anderson, P.N. et al. (2009) Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther., 16, 509-520.
162. Maheshri, N., Koerber, J.T., Kaspar, B.K. and Schaffer, D.V. (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol., 24, 198-204.
163. Koerber, J.T., Jang, J.H. and Schaffer, D.V. (2008) DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther., 16, 1703-1709.
164. Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A. and Kay, M.A. (2008) In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol., 82, 5887-5911.
165. Excoffon, K.J., Koerber, J.T., Dickey, D.D., Murtha, M., Keshavjee, S., Kaspar, B.K., Zabner, J. and Schaffer, D.V. (2009) Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl Acad. Sci. USA, 106, 3865-3870.
166. Yang, L., Jiang, J., Drouin, L.M., Agbandje-McKenna, M., Chen, C., Qiao, C., Pu, D., Hu, X., Wang, D.Z., Li, J. et al. (2009) A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl Acad. Sci. USA, 106, 3946-3951.
167. Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.C., Samulski, R.J. and McCown, T.J. (2010) Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther., 18, 570-578.
168. Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., Lee, S.K., Shankar, P. and Manjunath, N. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448, 39-43.
169. Hajitou, A., Trepel, M., Lilley, C.E., Soghomonyan, S., Alauddin, M.M., Marini, F.C., Restel, B.H., Ozawa, M.G., Moya, C.A., Rangel, R. et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell, 125, 385-398.
170. Staquicini, F.I., Ozawa, M.G., Moya, C.A., Driessen, W.H., Barbu, E.M., Nishimori, H., Soghomonyan, S., Flores, L.G., Liang, X., Paolillo, V. et al. (2011) Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest., 121, 161-173.
171. Jiang, L., Rampalli, S., George, D., Press, C., Bremer, E.G., O'Gorman, M.R. and Bohn, M.C. (2004) Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Ther., 11, 1057-1067.
172. Candolfi, M., Xiong, W., Yagiz, K., Liu, C., Muhammad, A.K., Puntel, M., Foulad, D., Zadmehr, A., Ahlzadeh, G.E., Kroeger, K.M. et al. (2010) Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc. Natl Acad. Sci. USA, 107, 20021-20026.
173. Han, Y., Chang, Q.A., Virag, T., West, N.C., George, D., Castro, M.G. and Bohn, M.C. (2010) Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors. Gene Ther., 17, 616-625.
174. Ye, X., Rivera, V.M., Zoltick, P., Cerasoli, F., Schnell, M.A., Gao, G., Hughes, J.V., Gilman, M. and Wilson, J.M. (1999) Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science, 283, 88-91.
175. Sanftner, L.M., Rivera, V.M., Suzuki, B.M., Feng, L., Berk, L., Zhou, S., Forsayeth, J.R., Clackson, T. and Cunningham, J. (2006) Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol. Ther., 13, 167-174.
176. Alper, J. (2009) Geron gets green light for human trial of ES cell-derived product. Nat. Biotechnol., 27, 213-214.
177. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872.
178. Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, S. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-1920.
179. Maherali, N. and Hochedlinger, K. (2008) Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell, 3, 595-605.
180. Carey, B.W., Markoulaki, S., Hanna, J., Saha, K., Gao, Q., Mitalipova, M. and Jaenisch, R. (2009) Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl Acad. Sci. USA, 106, 157-162.
181. Sommer, C.A., Stadtfeld, M., Murphy, G.J., Hochedlinger, K., Kotton, D.N. and Mostoslavsky, G. (2009) Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells, 27, 543-549.
182. Lewitzky, M. and Yamanaka, S. (2007) Reprogramming somatic cells towards pluripotency by defined factors. Curr. Opin. Biotechnol., 18, 467-473.
183. Kustikova, O., Fehse, B., Modlich, U., Yang, M., Dullmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z. and Baum, C. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science, 308, 1171-1174.
184. Kane, N.M., Nowrouzi, A., Mukherjee, S., Blundell, M.P., Greig, J.A., Lee, W.K., Houslay, M.D., Milligan, G., Mountford, J.C., von Kalle, C. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Mol. Ther., 18, 2139-2145.
185. Gutierrez-Aranda, I., Ramos-Mejia, V., Bueno, C., Munoz-Lopez, M., Real, P.J., Macia, A., Sanchez, L., Ligero, G., Garcia-Parez, J.L. and Menendez, P. (2010) Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells, 28, 1568-1570.
186. Yamashita, T., Kawai, H., Tian, F., Ohta, Y. and Abe, K. (2010) Tumorigenic development of induced pluripotent stem cells in ischemic mouse brain. Cell Transplant., [Epub ahead of print, 5 November].
187. Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G.P., Berry, C.C., Martinache, C., Rieux-Laucat, F., Latour, S., Belohradsky, B.H. et al. (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363, 355-364.
188. Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., Mingozzi, F., Bennicelli, J.L., Ying, G.S., Rossi, S. et al. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 374, 1597-1605.